» Articles » PMID: 11997671

Role of the CC Chemokine Receptor 9/TECK Interaction in Apoptosis

Overview
Journal Apoptosis
Publisher Springer
Date 2002 May 9
PMID 11997671
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Chemokine receptors are members of the G protein coupled receptor (GPCR) supergene family whose expression is highly restricted to hematopoietic cells. Although the primary role of chemokine and chemokine receptor interaction is believed to be regulation of chemotaxis of leukocytes, subsequent information clearly suggests that multiple immune regulatory functions are attributed to chemokine receptor signaling. We recently showed that activation of the CC chemokine 9 receptor (CCR9), a thymus-specific chemokine receptor, led to potent cFLIP(L)-independent resistance to cycloheximide-induced apoptosis and modest resistance to Fas-mediated apoptosis possibly via activation of multiple signaling components involving Akt and glycogen synthase kinase 3beta. The fact that these two apoptotic signals involve activation of similar arrays of death execution machinery such as caspase-8, caspase-9, or caspase-3, suggests that chemokine receptor signaling may provide a wide range of antiapoptotic activities to hematopoietic cells under certain biological conditions. GPCR is a large family of cell surface receptors, many of which are critically involved in hormonal and behavioral control. Recent observations also suggest that GPCR signaling plays a pivotal role in immune cell activation. Heterotrimeric G protein is an integral part of GPCR signaling. Thus, dissection of signaling components involved in the CCR9-mediated antiapoptosis could be a framework for cell survival mechanisms and may provide options for therapeutic interventions for neurdegenerative diseases or T cell malfunctioning.

Citing Articles

CCR4 as a Therapeutic Target for Cancer Immunotherapy.

Yoshie O Cancers (Basel). 2021; 13(21).

PMID: 34771703 PMC: 8583476. DOI: 10.3390/cancers13215542.


Functional characterization of ferret CCL20 and CCR6 and identification of chemotactic inhibitors.

Qin S, Klamar C, Junecko B, Craigo J, Fuller D, Reinhart T Cytokine. 2013; 61(3):924-32.

PMID: 23360828 PMC: 3595334. DOI: 10.1016/j.cyto.2012.12.015.


Pituitary-ovary-spleen axis in ovulation.

Oakley O, Frazer M, Ko C Trends Endocrinol Metab. 2011; 22(9):345-52.

PMID: 21600783 PMC: 3161174. DOI: 10.1016/j.tem.2011.04.005.


CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion.

Johnson-Holiday C, Singh R, Johnson E, Grizzle W, Lillard Jr J, Singh S World J Surg Oncol. 2011; 9:46.

PMID: 21539750 PMC: 3110128. DOI: 10.1186/1477-7819-9-46.


CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion.

Johnson-Holiday C, Singh R, Johnson E, Singh S, Stockard C, Grizzle W Int J Oncol. 2011; 38(5):1279-85.

PMID: 21344163 PMC: 3760515. DOI: 10.3892/ijo.2011.953.